Drug-eluting balloons for peripheral artery disease: A meta-analysis of 7 randomized clinical trials and 643 patients

2013 ◽  
Vol 168 (1) ◽  
pp. 570-571 ◽  
Author(s):  
Giuseppe Biondi-Zoccai ◽  
Giuseppe Sangiorgi ◽  
Fabrizio D'Ascenzo ◽  
Andrea Zuffi ◽  
Marzia Lotrionte ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Peripheral Artery Disease ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Peripheral Artery ◽  
Drug Eluting ◽  
Artery Disease

scholarly journals Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease

2019 ◽  
Vol 106 (4) ◽  
pp. 319-331 ◽  
Author(s):  
J. Golledge ◽  
T. P. Singh ◽  
C. Alahakoon ◽  
J. Pinchbeck ◽  
L. Yip ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Peripheral Artery Disease ◽  
Meta Analysis ◽  
Home Exercise ◽  
Peripheral Artery ◽  
Artery Disease

scholarly journals Paclitaxel- and Sirolimus-coated Balloons in Peripheral Artery Disease Treatment: Current Perspectives and Concerns

2021 ◽  
Vol 4 ◽  
Author(s):  
Masayuki Mori ◽  
Atsushi Sakamoto ◽  
Rika Kawakami ◽  
Yu Sato ◽  
Hiroyuki Jinnouchi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Peripheral Artery Disease ◽  
Lower Risk ◽  
Meta Analysis ◽  
Therapeutic Index ◽  
Randomised Trials ◽  
Peripheral Artery ◽  
Disease Treatment ◽  
Artery Disease ◽  
Dose Dependent

Drug-coated balloons (DCBs) have become an established therapy for the treatment of above-the-knee peripheral artery disease. The paclitaxel DCB has shown clinical benefit in terms of patency and freedom from re-intervention in multiple randomised trials. However, a recent meta-analysis has suggested an association between mortality and the use of paclitaxel-coated devices. Sirolimus is another potential choice of anti-proliferative agent for use in DCBs because of its wider therapeutic index and lower risk for dose-dependent toxicity. More recently, encapsulating sirolimus in micro-reservoirs or polymers has facilitated the development of effective sirolimus DCBs, some of which are available in Europe and Asia. In this review, the authors focus on paclitaxel and sirolimus DCB technologies from the standpoint of drug characteristics and clinical trials.

Sign in / Sign up

Export Citation Format

Share Document